Current Issue 1 March 2012, Vol. 82, No. 3
Full Table of ContentsA Warm Welcome to Dr. Zietman
With the January 2012 issue, Anthony L. Zietman, MD, FASTRO, begins his term as Editor-in-Chief of the Red Journal, taking up the reins from James Cox. Elsevier and ASTRO welcome Dr. Zietman to the Journal and look forward to its continued success under his leadership.
Read ASTRO press release.
Read Dr. Zietman's editorial from the January issue.
Read Dr. Wilson's tribute to Dr. Cox.
CME Article
- Treatment of Locally Advanced Pancreatic Cancer: The Role of Radiation Therapy
Kimberly Johung, Muhammad Wasif Saif, Bryan W. Chang
Issue Highlights
- Oncology Scan
Thomas Buchholz, M.D., Red Journal Senior Editor, scans the oncology literature to bring you summaries and commentary on recent breast cancer articles that he feels are a “must read” for radiation oncologists.
- Concomitant Cisplatin and Hyperfractionaed Radiotherapy in Locally Advanced Head-and-Neck Cancer: 10-year Follow-Up of a Randomized Phase III Trial (SAKK 10/94)
This report describes the final results of SAKK 10/94 with a median follow-up of 9.5 years. In both arms patients with squamous carcinoma of the head and neck received hyper-fractionated radiation therapy (1.2Gy bid to a total dose of 74Gy) with the experimental arm receiving concomitant cisplatin in addition. The improvements in loco-regional control, disease-free and metastasis-free survival described in earlier reports were maintained but cisplatin did not increase late major toxicity.
- Phase I Clinical Trial Assessing Temozolamide and Tamoxifen With Concomitant Radiotherapy for Treatment of High-Grade Glioma
The proliferation of high-grade gliomas may be partly dependent on protein kinase C-mediated pathways. Tamoxifen has been shown in vitro to inhibit protein kinase C through estrogen receptor-independent antineoplastic effects. This Phase I trial determined the maximal tolerated dose (MTD) of tamoxifen to be 100mg/m2 when given with temozolomide and concurrent RT to patients with high-grade gliomas and sets the stage for Phase II studies and beyond.
- Long-Term Outcomes from a Prospective Trial of Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer
This report describes results from a prospective study in which 67 men with low-risk prostate cancer were treated to a total dose of 36.25Gy in 5 fractions. With a median follow-up of 2.7 years, late grade 3 or higher morbidities appeared infrequent although there has not yet been sufficient time to assess cancer control. This study and others similar will be closely followed in the years ahead as such treatment has the potential to change the paradigm in prostate cancer.
- IMRT for Image-Guided Single Vocal Cord Irradiation
Physicists in the Netherlands have developed a creative technique for irradiating a single vocal cord using IMRT and in this comparative study they demonstrate the potential gains of their approach over more conventional approaches. Significant reductions in dose to the contralateral cord and arytenoid were achieved without loss of target coverage. It is hoped that this will translate into real clinical gains.
-
Online Image-based Monitoring of Soft-tissue Displacements for Radiation Therapy of the Prostate27 January 2012
-
Projected Second Tumor Risk and Dose to Neurocognitive Structures After Proton Versus Photon Radiotherapy for Benign Meningioma27 January 2012
-
Evaluation of Field-in-Field Technique for Total Body Irradiation27 January 2012
-
Treatment Outcome of Medium-Dose-Rate Intracavitary Brachytherapy for Carcinoma of the Uterine Cervix: Comparison with Low-Dose-Rate Intracavitary Brachytherapy27 January 2012
-
Is There an Additional Value of 11C-Choline PET-CT to T2-weighted MRI Images in the Localization of Intraprostatic Tumor Nodules?27 January 2012
Effect of Image-Guidance Frequency on Geometric Accuracy and Setup Margins in Radiotherapy for Locally Advanced Lung Cancer
